Erectile%20dysfunction News

News

Mirabegron may improve sexual function in adults with OAB

Audrey Abella, 20230413100000

Mirabegron, a ß3 adrenoceptor agonist, delivers benefit for both men and women with overactive bladder (OAB) who are experiencing sexual dysfunction, a systematic review and meta-analysis reports.

Chronic pelvic pain in men tied to severe sexual dysfunction

20230202110000

Men with urologic chronic pelvic pain syndrome (UCPPS) tend to suffer a more severe sexual dysfunction, including erectile (ED) and ejaculatory dysfunction, when compared to their healthy counterparts or patients with other chronic pain conditions, reveals a study.

Diabetes, smoking predict erectile dysfunction in men after radical prostatectomy

20221216130000

A recent study reports functional erection in a small proportion of men 3 months after undergoing radical prostatectomy (RP). Of these, nearly half have shown a decline in erectile function at 6 months. Of note, the presence of diabetes and a smoking history are associated with erectile dysfunction.

Thrice/week on par with twice/week ultrasound therapy for erectile dysfunction

20221022120000

Low-intensity pulsed ultrasound therapy three times per week has comparable therapeutic effects and safety as that of a twice-a-week session for mild-to-moderate erectile dysfunction (ED) in young and healthy men, reports a study.

Poor sleep quality may increase odds of erectile dysfunction

20220926110000

Sleep parameters are robust predictors of erectile dysfunction (ED), suggesting that poor sleep quality contributes to a greater likelihood of ED, reveals a study.

Mirabegron benefits men with OAB, erectile dysfunction

20220926080000

The selective β3-AR agonist mirabegron appears to confer benefits for both overactive bladder (OAB) symptoms and erectile dysfunction (ED) in some patients without compromising safety, as reported in a study.

Pessimistic personality linked to erectile dysfunction

20220925120000

Young men with type D personality (TDP) have a higher prevalence of erectile dysfunction (ED), according to a Taiwan study.

PDE5-I use poses no excess cardiovascular, mortality risk in diabetic men with ED

20220920060000

The presence of erectile dysfunction (ED) does not appear to confer an increased risk of cardiovascular disease (CVD) and mortality in men with diabetes mellitus (DM), with comparable risk of adverse cardiovascular events among users and nonusers of phosphodiesterase-5 inhibitors (PDE5-Is), which are used to manage ED, according to a study.

Low-intensity shock wave safe, effective on moderate erectile dysfunction

20220802130000

Men with moderate erectile dysfunction (ED) may benefit from having 12 sessions of low-intensity shock wave therapy (SWT) twice weekly for 6 weeks, with a treatment protocol of 5,000 impulses, 0.0096 mJ/mm2 energy flux density, and 5-Hz frequency, suggests a study.

Men with multiple sclerosis at risk of erectile dysfunction

20220801110000

Adult men with multiple sclerosis (MS) are more likely to develop erectile dysfunction (ED), indicating that MS is a potential predictor for ED occurrence, suggest the results of a meta-analysis.

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.